| ISIN | LU2041625737 |
|---|---|
| Valor Number | 49473279 |
| Bloomberg Global ID | |
| Fund Name | JSS Sustainable Equity - Future Health C USD dist |
| Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
| Fund Provider | J. Safra Sarasin Investmentfonds AG |
| Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
| Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Luxembourg |
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). The assets of the fund are mainly invested worldwide either directly (min. 67% of the SubFund’s assets) or indirectly in equity securities that offer an exposure to one or multiple emerging and transformational health trends. The Sub-Fund invests in leading companies and niche players whose products and services contribute to the improvement of health outcome and the dampening of rising healthcare costs. |
| Peculiarities |
| Current Price * | 113.97 USD | 30.10.2025 |
|---|---|---|
| Previous Price * | 114.29 USD | 29.10.2025 |
| 52 Week High * | 115.90 USD | 27.10.2025 |
| 52 Week Low * | 94.62 USD | 08.04.2025 |
| NAV * | 113.97 USD | 30.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 135,372,697 | |
| Unit/Share Assets *** | 497,250 | |
| Trading Information SIX | ||
| YTD Performance | +12.13% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
|---|---|---|
| YTD Performance (in CHF) | -0.99% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
| 1 month | +5.47% |
30.09.2025 - 30.10.2025
30.09.2025 30.10.2025 |
| 3 months | +10.77% |
30.07.2025 - 30.10.2025
30.07.2025 30.10.2025 |
| 6 months | +7.73% |
30.04.2025 - 30.10.2025
30.04.2025 30.10.2025 |
| 1 year | +5.24% |
30.10.2024 - 30.10.2025
30.10.2024 30.10.2025 |
| 2 years | +30.01% |
30.10.2023 - 30.10.2025
30.10.2023 30.10.2025 |
| 3 years | +8.04% |
31.10.2022 - 30.10.2025
31.10.2022 30.10.2025 |
| 5 years | +6.38% |
30.10.2020 - 30.10.2025
30.10.2020 30.10.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson | 8.00% | |
|---|---|---|
| Eli Lilly and Co | 7.24% | |
| Danaher Corp | 6.45% | |
| Sanofi SA | 6.21% | |
| argenx SE | 5.71% | |
| Boston Scientific Corp | 4.87% | |
| AbbVie Inc | 4.65% | |
| Fresenius SE & Co KGaA | 4.63% | |
| Merck & Co Inc | 4.63% | |
| Lonza Group Ltd | 4.45% | |
| Last data update | 30.09.2025 | |
| TER | 1.39% |
|---|---|
| TER date | 30.04.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | 1.40% |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |